Elective orthopaedic surgery for inhibitor patients.
We report on a series of 108 elective orthopaedic surgical procedures. It includes 88 radiosynoviortheses and 20 major orthopaedic procedures, performed on 51 patients at nine centres worldwide. The average age of patients was 28.5 years (range 5-40 years), and the average follow-up time was 2 years (range 1-5 years). There were 82 good results, 15 fair and 11 poor. In the synoviorthesis group (41 patients, 88 synoviortheses) the average age was 14.3 years (range 5-40 years) and the average follow-up was 6.5 years (range 1-10 years). There were 66 good results, 14 fair and eight poor. There were no complications. In the group of major orthopaedic procedures, the average age of the 10 patients was 32.5 years (range 27-40 years), and the average follow-up was 2.3 years (range 1-5 years). There were 16 good results, one fair and three poor. Postoperative bleeding complications occurred in three of the 20 major orthopaedic procedures performed (15% complications rate). They occurred in three patients treated with insufficient doses of recombinant activated factor VII. Despite such complications, the study has shown that haemophilic patients with inhibitors requiring elective orthopaedic surgery (EOS) can undergo such procedures with a high expectation of success. In other words, EOS is now possible in haemophilic patients with inhibitors, leading to an improved quality of life for these patients. Thorough analysis of each case as part of a multidisciplinary team will allow us to perform elective orthopaedic procedures in patients with inhibitors.
D000293:Adolescent; D000328:Adult; D019774:Blood Coagulation Factor Inhibitors / Q000097:blood*; D016063:Blood Loss, Surgical / Q000517:prevention & control; D002648:Child; D002675:Child, Preschool; D017558:Elective Surgical Procedures / Q000379:methods; D005164:Factor IX / Q000037:antagonists & inhibitors; D005167:Factor VII / Q000627:therapeutic use; D005169:Factor VIII / Q000037:antagonists & inhibitors; D015942:Factor VIIa; D005500:Follow-Up Studies; D006467:Hemophilia A / Q000150:complications* / Q000276:immunology; D002836:Hemophilia B / Q000150:complications* / Q000276:immunology; D006488:Hemostasis, Surgical / Q000379:methods; D006801:Humans; D007518:Isoantibodies / Q000097:blood; D008297:Male; D019637:Orthopedic Procedures / Q000379:methods*; D011994:Recombinant Proteins / Q000627:therapeutic use; D012720:Severity of Illness Index
D019774:Blood Coagulation Factor Inhibitors; D007518:Isoantibodies; D011994:Recombinant Proteins; D005167:Factor VII; D005169:Factor VIII; D005164:Factor IX; C103587:recombinant FVIIa; D015942:Factor VIIa